Boast­ing a late-stage Botox me-too, Evo­lus files for $75M IPO

Seek­ing to break Al­ler­gan’s dom­i­nance in the wrin­kle-re­duc­ing mar­ket, Evo­lus has filed for a $75 mil­lion IPO. As the Irvine, CA-based biotech is prepar­ing to launch a biosim­i­lar ver­sion of Botox, it plans to spend the cash on reg­u­la­to­ry, pre-com­mer­cial and com­mer­cial ac­tiv­i­ties.

DWP-450, Evo­lus’ lead prod­uct, has a BLA filed with the FDA and has a May 15, 2018 PDU­FA date. In-li­censed from South Ko­re­an firm Dae­woong in 2013, it is an a 900 kDa pu­ri­fied bot­u­linum tox­in type A com­plex called prabot­u­linum­tox­i­nA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER